Stroke risk among patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis

Yu Ree Kim,¹ In Cheol Hwang,¹,*,# Yong Joo Lee,¹,# Eun Bee Ham,¹ Dong Kyun Park,³ Sewan Kim⁴

¹Department of Family Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea. ²Department of Family Medicine, Catholic University Seoul St. Mary’s Hospital, Seoul, Republic of Korea. ³Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea. ⁴Shingil Yonsei Clinic, Seoul, Republic of Korea.

Kim YR, Hwang IC, Lee YJ, Ham EB, Park DK, Kim S. Stroke risk among patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Clinics. 2018;73:e177

*Corresponding author. E-mail: spfe0211@gmail.com
#These authors contributed equally to this work.

Increased stroke risk among chronic obstructive pulmonary disease patients has not yet been established. In this study, we conducted a systematic review and meta-analysis to assess stroke risk among chronic obstructive pulmonary disease patients. PubMed, EMBASE, and the Cochrane Library were systematically searched from database inception until December 31, 2016 to identify longitudinal observational studies that investigated the association between chronic obstructive pulmonary disease and stroke. Stroke risk was quantified by overall and subgroup analyses, and a pooled hazard ratio was calculated. Study quality was evaluated using the Newcastle-Ottawa Scale. Publication bias was assessed using Begg’s rank correlation test. Eight studies met the inclusion criteria. In a random-effects model, significantly increased stroke risk was observed among chronic obstructive pulmonary disease patients (hazard ratio, 1.30; 95% confidence interval, 1.18-1.43). In subgroup analyses stratified by stroke subtype, study quality, and adjustment by socioeconomic status, the association between increased stroke risk and chronic obstructive pulmonary disease patients was robust. Statistically significant publication bias was not detected. In summary, chronic obstructive pulmonary disease was found to be associated with increased stroke risk. Additional prospective studies are required to elucidate the mechanisms underlying the increase in stroke risk and identify effective preventive interventions.

KEYWORDS: Cerebrovascular Disease; Chronic Obstructive Pulmonary Disease; Meta-Analysis; Stroke.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterized by persistent and usually progressive airflow restriction (1). COPD may limit activity, compromise quality of life, and result in disability. As such, this disorder presents a major, incurable population health burden (2). In addition, COPD patients may suffer from additional systemic manifestations of the disorder. Comorbid medical conditions further contribute to disease severity, functional impairment, reduced quality of life, and poor clinical outcomes. Cardiovascular diseases (CVDs), including ischemic heart disease, atrial fibrillation, and heart failure, and cerebrovascular diseases are the most prevalent and fatal comorbidities of COPD (3).

While the coexistence of COPD and CVD is well established, whether COPD increases the individual’s risk for all types of CVD has not been confirmed. Shared risk factors, persistent inflammation, and vulnerability to infection have been proposed as mechanisms by which COPD and CVD might be linked (4). While there is evidence suggesting that COPD increases the risk of heart disease (4,5), studies conducted to date on the risk of stroke among COPD patients have generated conflicting results. A recent review of the current evidence on stroke risk among COPD patients was limited by a dependence on cross-sectional data, which precluded a firm establishment of causality between COPD and stroke (4).

To further investigate the relationship between COPD and stroke, we performed the present meta-analysis of longitudinal studies and evaluated incident stroke in COPD patient cohorts. The primary aim of this study was to clarify whether COPD patients are at increased risk of stroke. Secondary aims were to assess whether the association between COPD and stroke varies according to the type of stroke or the core adjusted variables, including socioeconomic status (SES). A systematic review of the literature on the association between stroke and COPD was undertaken in order to provide a comprehensive perspective on disease mechanisms in COPD and to identify potential strategies for stroke prevention among COPD patients.

METHODS

Search strategy

Three databases (PubMed, EMBASE, and the Cochrane Library) were systematically searched from their inception to December 31, 2016. The following search terms were used...
to identify potential studies for inclusion: (COPD OR chronic obstructive airways disease OR chronic obstructive bronchial disease OR emphysema OR chronic bronchitis) and (stroke OR cerebrovascular disease OR cerebrovascular accident OR cerebral ischemia OR ischemic stroke OR transient ischemic accident OR hemorrhagic stroke). No search filters were applied. We also identified additional papers by reviewing the relevant articles listed in the references. This review followed the meta-analysis of observational studies in epidemiology (MOOSE) guidelines.

Study selection and inclusion criteria

Primary studies investigating stroke occurrence among COPD patients were eligible for inclusion. Additional eligibility criteria were that each study had to report the risk of developing stroke (e.g., not stroke-related mortality) and provide measures of association (hazard ratio (HR), incidence ratio (IR), or odds ratio (OR)) and precision (confidence interval (CI)). To investigate causality, we further narrowed the inclusion criteria to include only observational studies using a longitudinal study design. In the case of multiple publications using the same study population, only the most recent, largest, or most relevant publication was selected for inclusion.

Data extraction

Databases searches and data extraction were conducted by two independent investigators (YRK and YJL). Disagreements were resolved through consultation with a third author (ICH). The following information was extracted from each study: first author, year of publication, country, study setting, study design, measures of association with the corresponding 95% CIs, and core adjusted variables. Fully adjusted measures of association were extracted from the included studies. The Newcastle-Ottawa Scale, which is mainly based on potential confounding variables in the study populations, was used to assess methodological study quality.

Statistical analysis

This investigation aimed to assess whether there is an increased risk of incident stroke among COPD patients compared to control subjects. Subgroup analyses were performed for stroke subtype (all types, ischemic stroke, or hemorrhagic stroke); study quality (low or high); and consideration of SES (unadjusted or adjusted). HRs (with 95% CIs) from the individual studies were pooled. Using well-established methods (6) for calculating the variance of log HR from each study, we converted the 95% CIs to their natural logarithmic value by dividing the range of the CI by 3.92. We used Higgins $I^2$ ($0$-$100\%$) to assess the heterogeneity across studies. When substantial heterogeneity ($I^2 \geq 50\%$) was observed, we used the DerSimonian and Laird random-effects model as previously described (7). Random-effects models attempt to generalize findings beyond the included studies by assuming that the selected studies are random samples from a larger population (8). We also assessed publication bias using Begg’s rank correlation test. Stata software (version 12.1, StataCorp, College Station, TX, USA) was used for all statistical analyses.

RESULTS

Figure 1 presents the flow diagram of the identification of relevant studies. From the 3,048 articles that were initially retrieved, 233 underwent abstract review, and 18 articles underwent full-text review. Ten articles were subsequently excluded for the following reasons: no relevant control group (n=4); no separate estimate of COPD association with stroke (n=4); or no estimates on exacerbated COPD (n=2). A total of eight studies were included in the final analysis.

The observed association between COPD and stroke risk remained robust in subgroup analyses by stroke subtype, study quality, and adjustment for SES (Table 2). Interestingly, high-quality studies and studies that adjusted for SES variables tended to have smaller effect sizes. Funnel plot asymmetry among studies was not observed ($p=0.135$; Figure 3).

DISCUSSION

As comorbidities may substantially influence the severity and prognosis of COPD, studies exploring the associations between specific comorbidities and COPD are urgently needed. Stroke carries a significant risk of morbidity and mortality and is one of the most common causes of death and severe disability. Increased risk of stroke among COPD patients will increase the burden on their caregivers, whom are prone to adverse mental health when looking after COPD or stroke patients (9,10). Stroke may also contribute to pulmonary dysfunction due to impaired cough and/or weakness of respiratory muscles, resulting in an increased propensity for pneumonia (11). Accordingly, incident stroke in COPD can accelerate and further increase mortality risk. In our pooled analysis, COPD patients were found to have a 30% increased risk of developing stroke compared with non-COPD subjects. The observed association between COPD and stroke risk remained robust in subgroup analyses by stroke subtype and after adjustment for core variables. These results suggest that stroke risk should be closely monitored and controlled in patients with COPD.

Our subgroup analyses suggest that the increased stroke risk among COPD patients is not merely due to confounding by common risk factors, such as smoking, metabolic comorbidities, or SES. There is no doubt that cigarette smoking is associated with an increased risk of CVD, including stroke, and indeed, smoking has been shown to be associated with preclinical brain changes on magnetic resonance imaging (12). However, in prior studies of COPD and stroke, risk estimates were reduced by only approximately 10% after adjusting for smoking (13,14). In addition, cerebral small vessel disease has been shown to be significantly more prevalent among smokers with COPD than smokers without COPD (15), suggesting an additional pathogenic effect of COPD beyond the harm from smoking itself. Socioeconomic inequalities may also potentially account for disparities among risk factors (16); however, in our analysis, SES did not critically impact the observed associations between COPD and increased stroke risk, which supports the existence of a COPD-specific effect.
Potential mechanisms by which COPD and stroke might be linked include increased systemic inflammation (for example, resulting in elevated interleukin-6 and C-reactive protein levels) and increased oxidative stress (17). COPD is a persistent airway inflammatory process and can potentially cause a continuous spillover of inflammatory mediators from the lungs into the bloodstream (18). Many human studies have demonstrated increased serum levels of inflammatory and oxidative stress markers in COPD patients compared to controls (19,20). This dispersion of pro-inflammatory factors from the lungs may contribute to endothelial dysfunction and promote a pro-coagulative state, which may then lead to atherothrombosis, thereby providing a potential mechanistic link between COPD and the increased risk of cerebrovascular events (18). Furthermore, pro-inflammatory cytokines, including interleukin-6 and tumor necrosis factor alpha (TNF-α), were found to be elevated in depression (21). Depression is a common comorbidity of COPD (22) and stroke (23). This observation further strengthens the neuro-immunological link among smoking, cardiovascular risk factors, COPD and stroke (24). Reduced lung function in COPD patients has been found to be inversely associated with incident atrial fibrillation, another condition that might predispose patients to stroke (31). COPD represents more than impaired lung function, but reduced lung capacity itself, regardless of the cause, has been associated with increased risk of atrial fibrillation (32,33), stroke (34,35) and CVD mortality (36).

In the current study, although the majority of stroke events among COPD patients were of the ischemic type, the association between COPD and the risk of hemorrhagic stroke was also robust. Levels of plasminogen activator inhibitor-1 (PAI-1), a major inhibitor of fibrinolysis, were found to be higher in COPD patients and may contribute to thrombosis and ischemic stroke among these patients (37). Plasminogen activators were found to be beneficial for patients with mild stroke (38). However, additional study is required to evaluate the efficacy and safety of plasminogen activators as a treatment for stroke among COPD patients. Some risk factors are shared across all stroke subtypes, while others are differentially related (39). Aging and smoking are known to disrupt the blood-brain barrier (40,41), which may contribute to the increased risk of hemorrhagic stroke among COPD patients. High blood pressure is also a major risk factor for hemorrhagic stroke (42), and accumulation of blood within the brain may rapidly lead to damage due to mechanical injury and increased pressure (43). Prevalent use of anticoagulant
Table 1 - Characteristics of studies reporting the risk of incident stroke among COPD patients.

| First author, year | Country     | Setting                           | Design            | Outcomes | Stroke risk (95% CI)                  | Adjusted variables other than age and sex | NOS |
|-------------------|-------------|-----------------------------------|-------------------|----------|---------------------------------------|-------------------------------------------|-----|
| Söderholm, 2016 (49) | Sweden      | 103,419 COPD/103,419 without COPD | Nested case-control | First stroke | All: 1.24 (1.19-1.28) IS: 1.20 (1.15-1.25) HS: 1.32 (1.20-1.45)<sup>a</sup> | Metabolic comorbidities<sup>c</sup> Lifestyle (alcohol) SES Other comorbidities<sup>d</sup> | 8   |
| Portegies, 2016 (25) | Netherlands | 1,566 COPD/11,549 without COPD   | Prospective cohort | First stroke | All: 1.07 (0.89-1.27) IS: 1.10 (0.88-1.38) HS: 1.45 (0.86-2.45) | Metabolic comorbidities<sup>c</sup> Prior CVD Lifestyle (BMI and smoking) Others (hs-CRP and cIMT) | 9   |
| Lin, 2015 (50)      | Taiwan      | 10,413 COPD/41,652 without COPD  | Nested case-control | First stroke | All: 1.62 (1.49-1.77) IS: 1.64 (1.49-1.82)<sup>b</sup> HS: 1.18 (0.89-1.57)<sup>b</sup> | Metabolic comorbidities<sup>c</sup> Prior CVD Lifestyle (BMI, smoking, and alcohol) | 8   |
| Schneider, 2010 (13) | UK          | 2,482 new COPD/6,116 without COPD | Nested case-control | First stroke | All: 1.13 (0.92-1.38) | Metabolic comorbidities<sup>c</sup> Lifestyle (BMI and smoking) | 8   |
| Feary, 2010 (14)    | UK          | 26,915 COPD/1,136,898 without COPD | Nested case-control | First stroke | All: 1.39 (1.08-1.80)<sup>a</sup> | Metabolic comorbidities<sup>c</sup> Prior CVD Lifestyle (smoking) SES | 8   |
| Curkendall, 2006 (31) | Canada   | 11,493 COPD/22,986 without COPD  | Nested case-control | Any stroke   | All: 1.23 (0.68-2.22) | Metabolic comorbidities<sup>c</sup> Prior CVD | 7   |
| Sidney, 2005 (51)   | USA         | 36,931 COPD/44,137 without COPD  | Nested case-control | First stroke | All: 1.39 (1.25-1.54) | Metabolic comorbidities<sup>c</sup> | 7   |
| Huiart, 2005 (52)   | Canada      | 5,648 new COPD/general population | Nested case-control | Any stroke   | All: 1.27 (1.16-1.38) None | | 6   |

COPD, chronic obstructive pulmonary disease; CI, confidence interval; IS, ischemic stroke; HS, hemorrhagic stroke; CVD, cardiovascular disease; CRP, C-reactive protein; cIMT, carotid intima-media thickness; and NOS, Newcastle-Ottawa Scale.

<sup>a</sup> Recalculated.
<sup>b</sup> Not adjusted for lifestyle factors.
<sup>c</sup> Hypertension, diabetes, and hyperlipidemia.
<sup>d</sup> Including asthma, rheumatoid arthritis, lupus, and renal failure.
therapy for arrhythmias (3) in COPD patients may also partly explain the association between COPD and the increased risk of hemorrhagic stroke.

The present study has some limitations, mainly regarding study design, as it relied on data from studies using administrative healthcare databases. When using administrative
healthcare data, there exists uncertainty regarding the diagnoses of COPD and stroke; healthcare databases usually do not contain records of lung function tests and brain imaging studies. Records from these sources also lack information on several important characteristics, including lifestyle factors such as smoking status, alcohol consumption, and physical and sedentary activity, thus preventing further stratified analyses. Variation among adjusted variables might partially account for the high heterogeneity found in the current meta-analysis. Another limitation of the included studies was that there was insufficient information on medication effects. COPD patients frequently use medications that may induce an acute CVD episode, including anticholinergic agents and sympathomimetic medications (44,45). COPD patients may also require treatment with macrolides and quinolone antibiotics, which are both associated with increased risk of adverse cardiovascular side effects (46). Finally, in this meta-analysis, there were not enough studies from non-Western countries, such as Asian studies. Further research is required to study the risk of stroke among Asian patients with COPD. At present, there are reports that Asian patients with COPD and stroke are more likely to report negative health and functional status (47). To further clarify the relationship between COPD and stroke risk, well-designed, prospective cohort studies with collaborating interventional trials are required. Further basic science studies are also required to explore whether targeting oxidative stress and lung and systemic inflammatory pathways may provide effective approaches for preventing vascular injury.

In conclusion, the results of this study suggest that COPD increases the risk of stroke, independent of other shared CVD risk factors. Current knowledge on the most effective approach for reducing stroke risk in COPD patients is still limited. For example, anticoagulant therapy is indicated only for COPD patients with atrial fibrillation (48). Primary care physicians should pay close attention to CVD risk, including stroke risk, from the time of COPD diagnosis, and where appropriate, they should work more closely with cardiologists and neurologists to enable optimal vascular care for patients with COPD.

ACKNOWLEDGMENTS

This study was supported by the Senior-Friendly Product R&D Program funded by the Ministry of Health & Welfare throughout the Korea Health Industry Development Institute (HI14C145), which did not play any role in the study design, literature search, study selection, collection and analysis of data, interpretation of results, or drafting of the manuscript.

AUTHOR CONTRIBUTIONS

Kim YR, Hwang IC and Lee YJ contributed to the study conception and design, data acquisition and analysis, and manuscript drafting. All authors contributed to data interpretation and critical revisions of the manuscript. Hwang IC and Lee YJ contributed equally to this work.

REFERENCES

1. Vesti J, Hurud SS, Agusti AG, Jones PW, Vogelemeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-65, http://dx.doi.org/10.1164/rccm.201304-0590PP.

2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800, http://dx.doi.org/10.1016/S0140-6736(15)60992-4.

3. Cavailles A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Cobert C, Marchand-Adam S, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454-75, http://dx.doi.org/10.1183/09059180.0008612.

4. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular complications in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631-9, http://dx.doi.org/10.1016/S2213-2600(15)00241-6.

5. Roversi S, Fabbi LM, Sin DD, Hawkins NM, Agusti A. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am J Respir Crit Care Med. 2016;194(11):1319-36, http://dx.doi.org/10.1164/rccm.201604-0690OS.

6. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88, http://dx.doi.org/10.1016/0197-2456(86)90101-2.

7. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58, http://dx.doi.org/10.1002/sim.1186.

8. Cheung MW, Ho RC, Lim Y, Mak A. Conducting a meta-analysis: basics and good practices. Int J Rheum Dis. 2012;15(2):129-35, http://dx.doi.org/10.1111/j.1746-5562.2012.01721.x.

9. Bernabeu-Mora R, Garcia-Guilamon G, Montilla-Herrador J, Escolar-Reina P, Garcia-Vidal JA, Medina-Mirapeix F. Rates and predictors of depression status among caregivers of patients with COPD hospitalized for acute exacerbations: a prospective study. Int J Chron Obstruct Pulmon Dis. 2016;11:3199-205, http://dx.doi.org/10.2147/ICOP.S118109.

10. Loh AZ, Tan JS, Zhang MW, Ho RC. The Global Prevalence of Anxiety and Depressive Symptoms Among Caregivers of Stroke Survivors. J Med Assoc Dir Assoc. 2017;18(2):111-6, http://dx.doi.org/10.1097/jamda.2016.08.014.

11. Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. 2009;8(1):105-18, http://dx.doi.org/10.1016/S1474-4422(09)70266-2.

12. Domino EF. Tobacco smoking and MRI/MS brain abnormalities compared to nonsmokers. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1778-81, http://dx.doi.org/10.1016/j.pnpbp.2007.10.004.

13. Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol. 2010;25(4):253-60, http://dx.doi.org/10.1007/s10654-010-9425-7.

14. Furry JR, Rodrigues IC, Smith CJ, Hubbard RB, Gibbons JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(5):956-62, http://dx.doi.org/10.1136/thx.2009.128002.

15. Lahousse L, Vernooy MW, Darweesh SK, Akouldad S, Loth DW, Joes GF, et al. Chronic obstructive pulmonary disease and cerebral microbleeds. The Rotterdam Study. Am J Respir Crit Care Med. 2013;188(7):783-8, http://dx.doi.org/10.1164/rccm.201303-0455OC.

16. Sommer I, Griebl E, Mahlknecht P, Thaler K, Bouskill K, Gartlehner G, et al. Socioeconomic inequalities in non-communicable diseases and their risk factors: an overview of systematic reviews. BMC Public Health. 2015;15:914, http://dx.doi.org/10.1186/s12889-015-2227-y.

17. Austin V, Crick PJ, Bozinovski S, Miller AA, Vlahos R. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci. 2016;130(13):1039-50, http://dx.doi.org/10.1042/CS20160433.

18. Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012;186(1):11-16, http://dx.doi.org/10.1164/rccm.201203-0455PP.

19. Kirkham PA, Barnes PA. Chronic stress in COPD. Chest. 2013;144(1):266-73, http://dx.doi.org/10.1378/chest.12-2664.

20. Sidney NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65(10):930-6, http://dx.doi.org/10.1136/thx.2009.130260.

21. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 2012;139(3):230-9, http://dx.doi.org/10.1016/j.jad.2011.08.003.

22. Zhang MW, Ho RC, Cheung MW, Fu E, Mak A. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Cen Hosp Psychiatry. 2013;33(3):217-23, http://dx.doi.org/10.1016/j.jgenhosppsych.2013.05.009.

23. Kakk K, Kong WY, Mak A, Sharma VK, Ho RC. Polymorphisms of the serotonin transporter gene and post-stroke depression: a meta-analysis. J Neurol Neuropsychiatr Clin Neurosci. 2013;84(3):322-8, http://dx.doi.org/10.1177/174481611246200C.

26. Patel AR, Kovessler BS, Donaldson GC, Mackay AJ, Singh R, George SN, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstruc-
obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(9):1091-9, http://dx.doi.org/10.1164/rccm.201306-1170OC.
27. Polosa R, Malerba M, Cacciola RR, Morjaria JB, Maugeri C, Prosperi G, et al. Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients. Intern Emerg Med. 2013;8(7):567-74, http://dx.doi.org/10.1007/s11739-011-0636-1.
28. Criner GJ, Connolly JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, et al. Siwmavastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201-10, http://dx.doi.org/10.1056/NEJMoA1403096.
29. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2014;129(9):1046-52, http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004050.
30. Li J, Agarwal SK, Alonso A, Blecker S, Chamberlain AM, London SJ, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016;387(10030):1817-26, http://dx.doi.org/10.1016/S0140-6736(16)30099-1.
31. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring Jr E, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16(1):63-70, http://dx.doi.org/10.1016/j.annepidem.2005.04.008.
32. Li J, Agarwal SK, Alonso A, Blecker S, Chamberlain AM, London SJ, et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2014;129(9):971-80, http://dx.doi.org/10.1161/CIRCULATIONAHA.113.040850.
33. Johnson LS, Juhlho T, Engstrom G, Nilsson PM. Reduced forced expiratory volume is associated with increased incidence of atrial fibrillation: the Malmo Preventive Project. Eur Respir J. 2014;44(6):182-8, http://dx.doi.org/10.1183/09031936.00005513.
34. Soderholm M, Zia E, Hedblad B, Engstrom G. Lung function as a risk factor for subarachnoid hemorrhage: a prospective cohort study. Stroke. 2012;43(10):2598-603, http://dx.doi.org/10.1161/STROKEAHA.112.658427.
35. Gulsvik AK, Gulsvik A, Skovlund E, Thelle DS, Mow J, Humerfelt S, et al. Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function. Int J Chron Obstruct Pulmon Dis. 2017;12:981-7, http://dx.doi.org/10.2147/COPD.S126899.
36. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2003;124(6):1988-93, http://dx.doi.org/10.1378/chest.124.6.1952.
37. Waschki B, Wata H, Holz O, Magnus H, Olejnica B, Welte T, et al. Plasmogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function. Int J Chron Obstruct Pulmon Dis. 2017;12:981-7, http://dx.doi.org/10.2147/COPD.S126899.
38. Yeo LL, Ho R, Paliwal P, Ratha Krishna R, Sharma VK. Intravenously administered tissue plasminogen activator useful in milder strokes? A meta-analysis. J Stroke Cerebrovasc Dis. 2014;23(8):2156-62, http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2014.04.008.
39. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rav-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-23, http://dx.doi.org/10.1016/S0140-6736(10)60834-3.
40. Elaby M, Jackaman C, Mamo JC, Lam V, Dhalwal SS, Giles C, et al. Blood-brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immun Ageing. 2013;12:2, http://dx.doi.org/10.1186/1179-015-0029-9.
41. Kaisar MA, Prasad S, Cucullo L. Protecting the BBB endothelium against cigarette smoke-induced oxidative stress using popular antioxidants: Are they really beneficial? Brain Res. 2015;1627:90-100, http://dx.doi.org/10.1016/j.bbr.2015.09.018.
42. Wilson D, Charidimou A, Werring DJ. Advances in understanding spontaneous intracerebral hemorrhage: insights from neuroimaging. Expert Rev Neurother. 2014;14(6):661-78, http://dx.doi.org/10.1586/14737175.2014.918506.
43. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373(9675):1632-44, http://dx.doi.org/10.1016/S0140-6736(09)60371-8.
44. Singh S, Loke YK, Earnest P, Furberg CD. Pro-arrhythmic and pro-isaemic effects of inhaled anticholinergic medications. Thorax. 2013;68(1):114-6, http://dx.doi.org/10.1136/thoraxjnl-2011-201275.
45. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suisse S. Bronchodilator use and the risk of arrhythmia in COPD part 2: reassessment in the larger Quebec cohort. Chest. 2012;142(2):305-11, http://dx.doi.org/10.1378/chest.11-1597.
46. Owens RC Jr, Nelin TD. Antimicrobial-associated QT interval prolongation: Points of interest. Clin Infect Dis. 2006;43(15):1603-11, http://dx.doi.org/10.1086/508873.
47. Niti M, Ng TP, Kua EH, Ho RC, Tan CH. Depression and chronic medical illnesses in Asian older adults: the role of subjective health and functional status. Int J Cerebr Psychiatry. 2007;22(11):1087-94, http://dx.doi.org/10.1016/j.ipgp.1789.
48. Lainscak M, Darges N, Filippatos GS, Anker SD, Kremastinos DT. Atrial fibrillation in chronic non-cardiac disease: where do we stand? Heart. 2013;99:1415-20, http://dx.doi.org/10.1136/thoraxjnl-2011-201275.
49. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201-10, http://dx.doi.org/10.1056/NEJMoA1403096.
50. Lin HW, Chung CL, Lin YS, Yu CM, Lee CN, Bien MY. Inhaled pharmacotherapy and stroke risk in patients with chronic obstructive pulmonary disease: A nationwide population based study using two-stage approach. PLoS One. 2015;10(7):e0130102, http://dx.doi.org/10.1371/journal.pone.0130102.
51. Sidney S, Sorel M, Queeberberry CP Jr, DeLuise C, Lanes S, Eiser MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128(4):2640-6, http://dx.doi.org/10.1378/chest.2005.128.4.2640.